Spain's Grifols (GRLS.MC) said it had closed a $1.1 billion bond issue, completing the financing needed to buy U.S. peer Talecris (TLCR.O) in a bid to become the world's third largest maker of haemoderivative products. The seven-year bonds with an annual coupon of 8.25 percent were fully subscribed by investors from the United States and other countries, the company said. Grifols also has a $3.4 billion financing agreement to cover its acquisition of Talecris, which it estimates could cost up to $4.5 billion.
Source
